| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000008858 |
| Receipt No. | R000010400 |
| Official scientific title of the study | Clinical study to investigate the therapeutic effect of 1-kestose on atopic dermatitis |
| Date of disclosure of the study information | 2012/09/05 |
| Last modified on | 2017/03/13 (Ver. 9) |
| Basic information | ||
| Official scientific title of the study | Clinical study to investigate the
therapeutic effect of 1-kestose on atopic dermatitis |
|
| Title of the study (Brief title) | Effect of 1-kestose on atopic dermatitis | |
| Region |
|
|
| Condition | ||||
| Condition | Atopic dermatitis | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To examine the clinical effect of 1-
kestose, a fructo-oligosaccharide, on atopic dermatitis, based on a multicenter randomized controlled trial. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Phase II |
| Assessment | |
| Primary outcomes | Severity score based on the Severity
Scoring of Atopic Dermatitis (SCORAD) 6 weeks after the begining of the administration |
| Key secondary outcomes | 1. SCORAD scores 12 weeks after the
begining of the administration and 6 weeks after the end of the administration 2. Bifidobacterial count and strain structure, staphylococcus aureus count 3. Permeability test of the intestinal mucosa (lactulose/mannitol load test) 4. Bloot tests (white blood cell count, eosinophil count, immunoglobulin E, ImmunoCAP-ovalbumin/milk/mites, Thymus and Activation-Regulated Chemokine) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | YES |
| Institution consideration | Institution is considered as a block. |
| Blocking | YES |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intervention (1-kestose) group
Period: 12 weeks Dose: 1g/day (age < 1 year), 2g/day (1-3 years), or 3g/day (4-6 years). A half dose per time, twice per day. |
|
| Interventions/Control_2 | Control (maltose) group
Period and dose: same as the intervention group. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with atopic dermatitis
2. "Severe" or milder disease according to the "Guidelines for the Treatment of Atopic Dermatitis 2005" by the Japan Health Labour Sciences Research Group 3. Non-user of external corticosteroids or users of external corticosteroids that are classified as "strong" or weaker. |
|||
| Key exclusion criteria | 1. Users of external corticosteroids that
are classified as "very strong" or "stronger" 2. Patients who regularly use probiotics/prebiotics other than 1-kestose for therapeutic purposes 3. Patients who regularly use antibiotics 4. Patients who are judged as ineligible by doctor in charge |
|||
| Target sample size | 120 | |||
| Research contact person | |
| Name of lead principal investigator | Yasuhiro Koga |
| Organization | Tokai University School of Medicine |
| Division name | Laboratory for infectious disease |
| Address | Isehara, Kanagawa prefecture, 259-1193 Japan |
| TEL | 0463-93-1121 |
| YASUHIRO@is.icc.u-tokai.ac.jp | |
| Public contact | |
| Name of contact person | Yasuhiro Koga |
| Organization | Tokai University School of Medicine |
| Division name | Laboratory for infectious disease |
| Address | Isehara, Kanagawa prefecture, 259-1193 Japan |
| TEL | 0463-93-1121 |
| Homepage URL | |
| YASUHIRO@is.icc.u-tokai.ac.jp | |
| Sponsor | |
| Institute | Tokai University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | B Food Science, Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立病院機構福岡病院小児科
国立病院機構福岡東医療センター小児科 福岡大学病院小児科 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000010400 |